OBJECTIVE: To probe into the effects of dezocine on the proliferation and differentiation of osteoblasts MC3 T3-E1 and the Wnt/β-catenin signaling pathway. METHODS: MC3 T3-E1 cells were treated with dezocine at concentrations of 0

5

10

20

40 and 80 μg/mL for 48 hours

cell counting kit-8（CCK-8） was used to detect the cell survival rate and calculate the half inhibitory concentration(IC

50

). MC3 T3-E1 cells were divided into control group

dezocine low concentration group（10 μg/mL）

dezocine medium concentration group（20 μg/mL）

dezocine high concentration group（40 μg/mL） and dezocine high concentration+ lithium chloride（LiCl） group（40 μg/mL+20 μmol/L）

the CCK-8 was used to detect cell survival rate; alkaline phosphatase（ALP） detection kit was used to detect the ALP activity; the alizarin red staining was used to detect cellular calcified nodules; the Western blot was used to detect the expression levels of osteogenic differentiation related protein [Runt-related transcription factor 2（RUNX2）

osteopontin（OPN）

osteocalcin（OCN）] and Wnt/β-catenin pathway related proteins（Wnt3 a

β-catenin） in the cells. RESULTS: The IC

50

of MC3 T3-E1 cells to dezocine was about 20 μg/mL; compared with the control group

the cell survival rate

ALP activity

number of calcified nodules

expression levels of RUNX2

OPN

OCN

Wnt3 a and β-catenin protein in dezocine low

medium and high concentration groups were decreased successively

with statistically significant difference（P

<

0.05）; compared with dizocine high concentration group

the cell survival rate

ALP activity

number of calcified nodules

the expression levels of RUNX2

OPN

OCN

Wnt3 a and β-catenin protein in dezocine high concentration+LiCl group were significantly higher

with statistically significant difference（P

<

0.05）. CONCLUSIONS: Dezocine can inhibit the proliferation and differentiation of osteoblasts MC3 T3-E1 by inhibiting the Wnt/β-catenin signaling pathway.